The hypereosinophilic syndrome: clinical features, laboratory findings and treatment.
D000925:Anticoagulants / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002493:Central Nervous System Diseases / Q000209:etiology; D004719:Endomyocardial Fibrosis / Q000209:etiology / Q000628:therapy; D004802:Eosinophilia / Q000150:complications* / Q000276:immunology* / Q000628:therapy; D005208:Fasciitis / Q000209:etiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D006973:Hypertension / Q000209:etiology; D008297:Male; D009220:Myositis / Q000209:etiology; D011239:Prednisolone / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D011657:Pulmonary Eosinophilia / Q000209:etiology; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D013156:Splenectomy; D013577:Syndrome; D013923:Thromboembolism / Q000188:drug therapy / Q000209:etiology
D000925:Anticoagulants; D011239:Prednisolone; D006918:Hydroxyurea